ReviewACS omega2026
Transforming Coagulation Testing: The Role of Biosensors in Prothrombin Time (PT) Measurement.
Review in ACS omega, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
A key component of blood coagulation evaluation, prothrombin time (PT) measurement is used to diagnose clotting abnormalities, track anticoagulant treatments, and evaluate liver function. Despite their clinical significance, traditional PT testing techniques frequently depend on centralized laboratory setups, which can be costly, time-consuming, and unavailable to many patients. New developments in biosensor technology provide revolutionary ways to overcome these restrictions. This article discusses the cutting-edge field of biosensors for PT monitoring, going over fundamental ideas, current developments, and potential applications. In order to facilitate quick, precise, and least intrusive coagulation monitoring, biosensors have used technologies including microfluidics, nanotechnology, and bio-MEMS (Micro-Electro-Mechanical Systems). Their usefulness in point-of-care (PoC) and home-based settings has been further increased by developments in device portability and integration with digital health platforms, promoting individualized healthcare. Strategies to increase sensitivity, selectivity, and cost-effectiveness are highlighted in the design and construction of PT biosensors. This thorough analysis emphasizes how important biosensors are to advancing PT assessment and enhancing clinical results. Biosensor technologies have the potential to revolutionize the diagnostic landscape by providing adequate and affordable coagulation monitoring solutions in various healthcare settings with sustained research and interdisciplinary cooperation.
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.